Hims & Hers in focus as Eli Lilly obesity drug sales disappoint

Eli Lilly (NYSE:LLY) shares sold off on Tuesday after the Indiana-based pharma giant’s Q4 and 2024 preliminary sales results for its obesity therapy tirzepatide fell short of Street forecasts. Novo Nordisk (NVO), the maker of the rival